Nadia Harbeck, MD, PhD, is Head of the Breast Center and holds the Chair for Conservative Oncology at the Dept. of OB&GYN, University of Munich (LMU), Germany. She obtained her specialist degree (OB&GYN) at the Technical University of Munich (TUM) and her medical degree from the University of Munich. From 2005 to 2009, she was an Assistant Professor and Head of Conservative Senology at TUM and from 2009 to 2011, she was Head of the Breast Center at the University of Cologne, Germany.
Professor Harbeck is a member of the expert panel issuing the yearly updated evidence-based AGO Guidelines for breast cancer therapy in Germany (www.ago-online.de). She is Scientific Director of the West German Study Group (www.wsg-online.com). From 2009 to 2015, she served on the executive board of the EORTC as the Chair of the translational research division. Professor Harbeck is Principal Investigator or Steering Committee member of numerous national and international clinical breast cancer trials, particularly with novel targeted compounds. Her translational research focuses on prognostic and predictive factors in breast cancer and other solid tumours. She has a strong interest in eHealth and is a co-developer of CANKADO, an international digital patient diary (www.cankado.com).
Professor Harbeck has authored more than 450 papers in peer-reviewed journals (cumulative impact factor > 2000; h-index 67) and is coordinating Editor-in-Chief of Breast Care (Karger Publishers). For her clinical translational research, she has received numerous awards, including the 2015 Bavarian Cancer Patient Award, the 2012 Claudia von Schilling Award, the 2008 EBCC Award (Emmanuel van der Schueren Lecture), the 2002 AGO Schmidt-Matthiesen Award, a 2001 AACR Award, and the 2001 ASCO Fellowship Merit Award for the highest-ranking abstract submitted. She is a panel member of several international breast cancer consensus conferences, such as for advanced breast cancer (ABC), breast cancer in young women (BCY), and early breast cancer (St Gallen).
Disclosures: Honoraria for lectures and consulting from Lilly, Novartis and Pfizer.
touchONCOLOGY – on demand
Watch internationally renowned breast cancer expert, Professor Nadia Harbeck, discuss key data in advanced breast cancer presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, USA.
Submit your question
What does the ASCO 2018 data mean for regional clinical practice?
Watch our video interview series with six clinical experts from Europe and Japan.
Topic: key clinical data from ASCO 2018 and their potential implications for optimizing clinical outcomes for patients with advanced breast cancer.